Sort   by:  
 Page size 
MetabolomicsDT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates

Nonalcoholic steatohepatitis (NASH) prevalence is rising with no pharmacotherapy approved. A major hurdle in NASH drug development is the poor translatability of preclinical studies to safe/effective clinical outcomes, and recent failures highlight a need to identify new targetable pathways. Dysr...

2023-04-13 | MTBLS5005 | MetaboLights
MetabolomicsNonalcoholic steatohepatitis (NASH) changes with S.Q. Leptin administrations
Not available
ORGANISM(S): Homo sapiens 
ST000677 | MetabolomicsWorkbench
MetabolomicsInvolvement of the Gut Microbes Romboutsia hominis and Akkermansia muciniphila in the Pathophysiology and Development of Nonalcoholic Steatohepatitis
Background Nonalcoholic steatohepatitis (NASH) represents a growing global health challenge due to its propensity to progress to irreversible hepatic disorders, including fibrosis, cirrhosis, and carcinoma. This study aimed to investigate the role of gut microbiota in the pathogenesis of NASH. We ha...
2025-06-23 | MTBLS12631 | MetaboLights
TranscriptomicsExpression data from mouse liver treated with metformin
Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes. We examined the effects of metformin, commonly used to treat patients with type 2 diabetes, on liver pathology in a non-diabetic NASH mouse model. Eight-week-old C57...
ORGANISM(S): Mus musculus 
2012-02-21 | E-GEOD-35961 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of rat non-alcoholic Steatohepatitis following feeding of high polyunsaturated fat diets
Most commonly used models of non-alcoholic steatohepatitis (NASH) are diets based on specific gene knockouts or represent extreme manipulations of diet. We have examined the effects of modest increased caloric intake and high dietary unsaturated fat content on the development of NASH in male rats us...
ORGANISM(S): Rattus norvegicus 
2008-06-20 | E-GEOD-8253 | biostudies-arrayexpress
ProteomicsMetabolomics and Lipidomics Screening Reveal Reprogrammed Signaling Pathways toward Cancer Development in Non-Alcoholic Steatohepatitis
Non-alcoholic fatty liver disease is now considered the most common form of chronic liver disease. It is a complex metabolic disease that silently progresses into non-alcoholic steatohepatitis (NASH). In fact, NASH is the tipping point for pericellular fibrosis, cirrhosis and hepatocellular carcinom...
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2021-08-19 | MSV000088003 | MassIVE
ProteomicsmARC1 knockdown protects liver from diet-induced NASH in mouse
Human genetic studies have identified several MARC1 variants as protective against non-alcoholic fatty liver diseases (NAFLD). The MARC1 variants are associated with reduced lipid profiles, liver enzymes, and liver-related mortality. However, the role of mitochondrial amidoxime reducing component 1 ...
ORGANISM(S): Mus Musculus (ncbitaxon:10090) 
2023-04-28 | MSV000091820 | MassIVE
ProteomicsAmelioration of nonalcoholic fatty liver disease by inhibiting the deubiquitylating enzyme RPN11
Nonalcoholic fatty liver disease (NAFLD) including its more severe manifestation, nonalcoholic steatohepatitis (NASH), is a global public health challenge. Here, we reveal a role for the deubiquitinating enzyme RPN11 in the development of NAFLD and NASH. Ablation of hepatic RPN11 markedly protected ...
ORGANISM(S): Homo Sapiens Mus Musculus 
PXD053163 |
ProteomicsSerum glycoprotein markers in non-alcoholic steatohepatitis and hepatocellular carcinoma
mzml files, normalized abundance files and sample annotation files provided in this repository
ORGANISM(S): Homo Sapiens 
2022-02-09 | MSV000088809 | MassIVE
MetabolomicsDistinct Human Hepatocyte Lipidomics Profiles for Nonalcoholic Steatohepatitis and In Vitro-Induced Steatosis
Not available
ORGANISM(S): Homo sapiens 
ST002057 | MetabolomicsWorkbench
Sort   by:  
 Page size